Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3b, Randomized, Active Controlled Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination With Methotrexate in Inducing Clinical Remission Compared to Methotrexate Monotherapy in Adults With Very Early RA

Next Previous
X
Search
Trial Profile

A Phase 3b, Randomized, Active Controlled Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination With Methotrexate in Inducing Clinical Remission Compared to Methotrexate Monotherapy in Adults With Very Early RA

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Mar 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abatacept (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms AVERT
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 16 Feb 2022 Results of post-hoc analysis assessing if clinical and magnetic resonance imaging (MRI) variables in patients with early RA who achieved remission with methotrexate and/or abatacept at 12 months could predict disease flare following treatment withdrawal, published in the Arthritis Research and Therapy.
    • 09 Nov 2021 Results (n=2087) of pooled analysis from 4 Randomized Controlled Trials (NCT00122382, NCT00929864, NCT01142726 and NCT02504268) assessing clinical outcomes among patients with SPEAR and non-SPEAR to understand the differential treatment impact of ABA on each ACR core measure, presented at the ACR Convergence 2021.
    • 09 Nov 2021 Results of pooled analysis from NCT00122382, NCT00929864, NCT01142726 and NCT02504268; comparing clinical outcomes of RA patients with enriched autoantibody biomarkers and early disease stage (SPEAR) to non-SPEAR, presented at the ACR Convergence 2021

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top